TXG

62.19

11.79% 6.56

Dopo l'orario di chiusura: 63.70 1.51 +2.43%

10 X Genomics Inc (TXG)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$55.63

Aprire:

$58.47

Volume 24 ore:

3.90M

Relative Volume:

1.21

Capitalizzazione di mercato:

$8.10B

Reddito:

$638.78M

Utile/perdita netta:

$-22.66M

Rapporto P/E:

-356.59

EPS:

-0.1744

Flusso di cassa netto:

$122.18M

1 W Prestazione:

+7.69%

1M Prestazione:

+42.18%

6M Prestazione:

+224.08%

1 anno Prestazione:

+363.76%

Intervallo 1D:

$57.83

$62.36

Intervallo di 1 settimana:

$55.25

$62.36

Portata 52W:

$11.16

$62.36

10 X Genomics Inc Stock (TXG) Company Profile

Nome

10 X Genomics Inc

Settore

Healthcare (1078)

Industria

Health Information Services (46)

Telefono

(925) 401-7300

Indirizzo

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Dipendente

1,178

Cinguettio

@10xgenomics

Prossima data di guadagno

2026-08-06

Ultimi documenti SEC

TXG's Discussions on Twitter

Compare TXG vs VEEV, BTSG, TEM, HQY

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
TXG 10 X Genomics Inc	62.19	7.25B	638.78M	-22.66M	122.18M	-0.1744
VEEV Veeva Systems Inc	251.00	39.43B	3.32B	941.65M	1.64B	5.6161
BTSG Brightspring Health Services Inc	59.33	11.77B	13.65B	169.86M	412.12M	1.0758
TEM Tempus Ai Inc	61.25	8.91B	1.36B	-302.91M	-219.93M	-1.7182
HQY Healthequity Inc	103.95	8.59B	1.34B	230.70M	440.96M	2.6695

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-03-31	Aggiornamento	William Blair	Mkt Perform → Outperform
2025-12-11	Downgrade	Citigroup	Buy → Neutral
2025-12-02	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2025-09-11	Iniziato	Piper Sandler	Neutral
2025-02-13	Downgrade	Leerink Partners	Outperform → Market Perform
2024-09-03	Iniziato	Leerink Partners	Outperform
2024-07-22	Aggiornamento	Jefferies	Hold → Buy
2024-07-18	Downgrade	JP Morgan	Overweight → Neutral
2024-07-10	Downgrade	Deutsche Bank	Buy → Hold
2024-06-27	Downgrade	Wolfe Research	Outperform → Peer Perform
2024-06-25	Downgrade	Guggenheim	Buy → Neutral
2024-06-03	Ripresa	Jefferies	Hold
2024-05-01	Downgrade	TD Cowen	Buy → Hold
2023-12-14	Iniziato	Guggenheim	Buy
2023-12-13	Iniziato	Wolfe Research	Outperform
2023-12-12	Aggiornamento	BofA Securities	Underperform → Neutral
2023-07-05	Ripresa	JP Morgan	Overweight
2023-05-10	Iniziato	Barclays	Overweight
2023-03-31	Iniziato	Stephens	Overweight
2023-02-02	Iniziato	UBS	Neutral
2022-12-14	Iniziato	Deutsche Bank	Buy
2022-08-18	Downgrade	Goldman	Neutral → Sell
2022-07-25	Iniziato	Canaccord Genuity	Buy
2022-07-15	Downgrade	BofA Securities	Neutral → Underperform
2022-07-15	Downgrade	William Blair	Outperform → Mkt Perform
2021-10-15	Ripresa	Cowen	Outperform
2021-09-14	Downgrade	BofA Securities	Buy → Neutral
2021-03-15	Iniziato	William Blair	Outperform
2020-12-02	Iniziato	Goldman	Neutral
2020-09-09	Iniziato	Morgan Stanley	Overweight
2020-07-10	Iniziato	Stifel	Buy
2020-03-05	Iniziato	Guggenheim	Buy
2020-01-07	Iniziato	Citigroup	Buy
2019-10-07	Iniziato	BofA/Merrill	Buy
2019-10-07	Iniziato	Cowen	Outperform
2019-10-07	Iniziato	JP Morgan	Overweight
2019-09-24	Iniziato	Evercore ISI	Outperform

Mostra tutto

10 X Genomics Inc Borsa (TXG) Ultime notizie

01:02 AM

10x Genomics’ Bid to Revive Patents Rejected by Federal Circuit - Bloomberg Law News

01:02 AM

12:11 PM

10x Genomics (NASDAQ:TXG) Reaches New 52-Week HighWhat's Next? - MarketBeat

12:11 PM

09:48 AM

10x Genomics stock hits 52-week high at $60.73 By Investing.com - Investing.com Canada

09:48 AM

09:38 AM

10x Genomics stock hits 52-week high at $60.73 - Investing.com

09:38 AM

03:23 AM

Bank of America Corp DE Has $20.48 Million Position in 10x Genomics $TXG - MarketBeat

03:23 AM

Aug 18, 2026

Director Sarah Teichmann Sells 7,551 Shares of 10x Genomics Inc (TXG) - GuruFocus

Aug 18, 2026

Aug 17, 2026

A Look at 10x Genomics Inc (TXG) After 3.4% Gain -- GF Value $18 - GuruFocus

Aug 17, 2026